Mega Genomics (6667) investor relations material

Executive summary

• H1 revenue rose 136.8% to RMB192.499m as ancillary services and related products expanded; net profit fell 9.2% to RMB24.751m amid lower margins from product and service mix changes.

• More than 26m tests had been performed by 30 June 2026; 127 testing solutions were offered, including 97 self-developed services, with operations spanning more than 340 Chinese cities.

Financial highlights

• Gross profit was RMB63.678m, up 5.9%; profit before tax was RMB30.962m versus RMB33.142m in H1 2025.

• Cost of sales rose 509.3% to RMB128.821m; selling and distribution expenses increased 38.3% to RMB14.4m.

• Basic and diluted EPS were both RMB0.12, versus RMB0.13 in H1 2025; RSUs had an anti-dilutive effect.

• Operating cash flow was RMB16.845m; cash and cash equivalents rose 2.2% from RMB415.6m at year-end 2025 to RMB424.6m at 30 June 2026.

Outlook and guidance

• Plans include upgrading and launching consumer genetic testing products, expanding cancer-screening lines, and increasing R&D investment and professional recruitment.

• Blood-methylation digestive cancer screening priorities include automation, lower production costs, and R&D and regulatory filings to improve sensitivity and specificity; qPCR colorectal and gastric cancer kits are in registration and filing, with certificates expected by 2027.

• A manufacturing laboratory is planned to broaden geographic coverage, shorten reporting cycles and reduce costs; selective acquisitions may complement products and technology.